EMA — authorised 11 November 2015
- Marketing authorisation holder: Baxalta Innovations GmbH
- Status: approved
EMA authorised Obizur on 11 November 2015
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. EMA authorised it on 11 November 2015.
Baxalta Innovations GmbH holds the EU marketing authorisation.